Headquartered in Heidelberg, Germany, EVI collaborates with partners across the world to pursue its mission.
Although malaria vaccine development remains an important activity for EVI, today EVI is dedicated to support and accelerate the development of effective, accessible, and affordable vaccines for other diseases of importance for global health.
[6] Each of the constituent members is represented on the Board of Directors, which approves policies, organisational strategy and budget.
[7] Each constituent member is represented in the General Assembly, which approves policies, organisational strategy and budget.
EVI's work is funded by donors including Coalition for Epidemic Preparedness Innovations (CEPI), European & Developing Countries Clinical Trials Partnership (EDCTP), European Union (EU), Global Health Innovative Technologies Fund (GHIT), Innovative Medicines Initiative (IMI), Nobelpharma Co., Ltd., World Health Organization - Special Programme for Research and Training in Tropical Diseases (TDR), the Dutch Ministry of Foreign Affairs,[8] the Danish International Development Agency (Danida), the Department of Foreign Affairs (Irish Aid),[9][10] the Dutch Research Council, the German Federal Ministry of Education and Research (BMBF) through KfW,[11] and the Swedish Ministry of Foreign Affairs, Swedish International Development Cooperation Agency (Sida).